Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells

BACKGROUND: Chronic myelogenous leukemia (CML) is a hematological stem cell disorder. Tyrosine kinase inhibitors (TKIs) are the standard treatments for CML, but a number of patients fail to respond effectively due to gene mutations. Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, has been shown to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Transl Med
Main Authors: Lu, Ying, Liu, Ling-Ling, Liu, Shou-Sheng, Fang, Zhi-Gang, Zou, Yong, Deng, Xu-Bin, Long, Zi-Jie, Liu, Quentin, Lin, Dong-Jun
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5029099/
https://ncbi.nlm.nih.gov/pubmed/27645552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-1012-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados